Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

BACKGROUND: Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies. Although immune-related adverse events (irAEs) associated with nivolumab are largely tolerable, severe irAEs have occurred in some...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Koji, Nakayama, Takayuki, Ito, Ayumu, Sato, Eiichi, Kitano, Shigehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819390/
https://www.ncbi.nlm.nih.gov/pubmed/31664934
http://dx.doi.org/10.1186/s12885-019-6138-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819390/
https://www.ncbi.nlm.nih.gov/pubmed/31664934
http://dx.doi.org/10.1186/s12885-019-6138-7

Ejemplares similares